FDAsafety guidance72% confidence
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Merck.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Ovarian Cancer
- Sub-indication
- General
Related signal: Merck's Sac-TMT Trial for Advanced Ovarian Cancer Aims to Improve Maintenance Treatment Outcomes